4.7 Article

Inflammatory cytokines-stimulated human muscle stem cells ameliorate ulcerative colitis via the IDO-TSG6 axis

Journal

STEM CELL RESEARCH & THERAPY
Volume 12, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13287-020-02118-3

Keywords

Human muscle stem cells; Inflammatory bowel disease; Indoleamine 2; 3-dioxygenase; TNF-stimulated gene 6; Kynurenine; Kynurenic acid; Aryl hydrocarbon receptor

Funding

  1. National Key R&D Program of China [2018YFA0107500]
  2. National Natural Science Foundation of China [81530043, 81930085, 81802845, 31900635]
  3. Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZN1201903]

Ask authors/readers for more resources

This study demonstrates that human muscle stem cells treated with inflammatory factors can alleviate symptoms of inflammatory bowel disease through IDO-mediated TSG-6 production. Mechanistically, tryptophan metabolites produced by IDO enhance TSG-6 expression via activation of the common receptor AHR.
BackgroundMuscle stem cells (MuSCs) are absolutely required for the formation, repair, and regeneration of skeletal muscle tissue. Increasing evidence demonstrated that tissue stem cells, especially mesenchymal stem cells (MSCs), can exert therapeutic effects on various degenerative and inflammatory disorders based on their immunoregulatory properties. Human mesenchymal stem cells (hMSCs) treated with interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) were reported to possess anti-inflammatory functions by producing TNF-stimulated gene 6 (TSG-6). However, whether human muscle stem cells (hMuSCs) also possess TSG-6 mediated anti-inflammatory functions has not been explored.MethodsThe ulcerative colitis mouse model was established by subjecting mice to dextran sulfate sodium (DSS) in drinking water for 7days. hMuSCs were pretreated with IFN-gamma and TNF-alpha for 48h and were then transplanted intravenously at day 2 of DSS administration. Body weights were monitored daily. Indoleamine 2,3-dioxygenase (IDO) and TSG-6 in hMuSCs were knocked down with short hairpin RNA (shRNA) and small interfering RNA (siRNA), respectively. Colon tissues were collected for length measurement and histopathological examination. The serum level of IL-6 in mice was measured by enzyme-linked immunosorbent assay (ELISA). Real-time PCR and Western blot analysis were performed to evaluate gene expression.ResultshMuSCs treated with inflammatory factors significantly ameliorated inflammatory bowel disease (IBD) symptoms. IDO and TSG-6 were greatly upregulated and required for the beneficial effects of hMuSCs on IBD. Mechanistically, the tryptophan metabolites, kynurenine (KYN) or kynurenic acid (KYNA) produced by IDO, augmented the expression of TSG-6 through activating their common receptor aryl hydrocarbon receptor (AHR).ConclusionInflammatory cytokines-treated hMuSCs can alleviate DSS-induced colitis through IDO-mediated TSG-6 production.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available